Table 1.
Baseline levels of total cholesterol (TC), HDL cholesterol (HDL), LDL cholesterol (LDL), TC/HDL ratio, triglycerides (TG) and Framingham score (FRS) across groups. Variable are expressed as means (±SD) or medians (Q1-Q3)
| Variable | Switches from 2NRTI + EFV to | Switches from 2NRTI + PI/r to | ||||
|---|---|---|---|---|---|---|
| DTG | EVG | RPV | DTG | EVG | RPV | |
| TC (mg/dl) | 198.5 (41.6) | 207.4 (40.7) | 196.5 (38.0) | 209.9 (41.0) | 203.7 (43.9) | 189.2 (47.1) |
| HDL (mg/dl) | 53.5 (16.7) | 49.3 (14.4) | 48.8 (13.8) | 48.8 (14.7) | 43.5 (12.3) | 48.8 (21.0) |
| TC/HDL (mg/dl) | 3.93 (1.1) | 4.4 (1.1) | 4.3 (1.4) | 4.65 (1.6) | 4.98 (1.6) | 4.2 (1.3) |
| LDL (mg/dl) | 117.0 (39.4) | 128.2 (32.6) | 120.3 (35.5) | 126.0 (33.7) | 123.5 (38.2) | 111.1 (39.5) |
| TG (mg/dl) | 114 (91.5–153.5) | 126.5 (106–171) | 109 (77–160) | 142 (84–215) | 150 (112–204) | 117 (85–189) |
| FRS (%) | 12.2 (6.7–25.3) | 6.7 (3.9–9.4) | 7.9 (4.7–13.2) | 9.4 (4.5–21.6) | 9.4 (4.5–15.6) | 7.3 (3.3–13.2) |
NRTI nucleoside reverse transcriptase inhibitors, EFV efavirenz, PI/r ritonavir-boosted protease inhibitors, DTG dolutegravir, EVG elvitegravir, RPV rilpivirine